ArticleHormones (Athens, Greece)2025
The relationship between the expression of ACE2 in peripheral blood and the prognosis of patients with adrenal adenoma and hypertension.
Article in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the relationship between ACE2 expression in peripheral blood and the prognosis of patients with adrenal adenoma and hypertension.
methodsWe recruited 80 patients with adrenal adenoma and hypertension (47 males, 33 females) treated between March 2021 and September 2022. Patients were divided into high ACE2 expression (n = 26) and low ACE2 expression (n = 54) groups. General patient data, blood pressure, serum potassium, creatinine, and hormone levels (cortisol, aldosterone, catecholamines) were compared. The frequency of hypertensive episodes with palpitations was recorded. Correlations between ACE2 expression and prognosis were analyzed using Pearson correlation and Cox regression models.
resultsThe ACE2 high expression group had significantly lower blood pressure, serum creatinine, and hormone levels (P < 0.001), but higher serum potassium (P < 0.001) compared to the low expression group. Over 3 months, the incidence of hypertensive episodes with palpitations was lower in the high expression group (7.69%) compared to the low expression group (24.07%) (P = 0.002). The frequency of episodes was also lower in the high expression group (P = 0.016). Pearson correlation analysis showed a negative correlation between ACE2 expression and poor prognosis (P < 0.001). Multivariate Cox regression confirmed low ACE2 expression as an independent risk factor for poor prognosis (P < 0.001).
conclusionHigh ACE2 expression is associated with improved cardiovascular and renal function and lower incidence of hypertensive episodes in patients with adrenal adenoma and hypertension, suggesting a protective role of ACE2 in mitigating hypertension-related complications. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
40153145What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.